Maedi-Visna Virus Vaccine
The Maedi-Visna (MV) lentivirus causes two slowly progressive eventually fatal diseases of sheep, Maedi, a progressive interstitial pneumonia, and Visna, a progressive demyelinating disease of the central nervous system. With our extensive experience and advanced platform, we are therefore confident in offering the best vaccine development services against maedi-visna virus. Creative Biolabs is a world leader in the field of vaccine development and can offer high-quality viral vaccines for use in prevention of viral infections. By consistently delivering the highest standards of quality, professionalism, and integrity, we want to become the partner of a choice for your requirements.
Maedi-visna virus (MVV) is an ovine retrovirus of the Lentivirus genus of the Retroviridae family, responsible for a slow virus infection of sheep leading to a progressing lymphoproliferative disease characterized by respiratory and nervous clinical signs and occasionally of the joints and/or mastitis which is invariably fatal. It affects multiple organs, but primarily the lungs where it causes interstitial pneumonia. The main target cells of MVV are of the monocyte/macrophage lineage and it does not infect T-lymphocytes or cause immune suppression like human immune deficiency virus (HIV). In addition, analogous to other lentiviruses, the genome of MVV includes three genes, gag, pol and env, also contains genes for regulatory proteins, i.e. vif, rev and tat.
Inactivated MMV Vaccines
The vaccination against lentivirus where vaccines are challenged by natural routes may be of general interest. The formalin-inactivated whole MVV vaccine with aluminum hydroxide was carried out and showed a good immune response to all major proteins of the virus. All vaccinees developed neutralizing antibodies to the vaccine strain. Compared with their unvaccinated siblings, natural infection was delayed in significant number of vaccinated twins born by seronegative and seroconverting mothers and vaccinated at birth with this inactivated MVV vaccine.
DVA Vaccines
The development of DNA vaccines may be the ideal approach to control the MVV infection. The strategy of a DNA vaccine is an antigen-encoding bacterial plasmid designed to mimic infections safely, with ability to generate both humoral and cellular long-lasting immune responses once it is delivered to the host. At the first step, the design of the vaccines is crucial, including the choice of the backbone vector and the nucleotide sequences to use as antigen-encoding sequences. Once constructed, the vaccines may be produced with high quality for use in in vitro and in vivo tests. There are several approaches may be later performed in order to enhance the effectiveness of the vaccines, such as the introduction of targeting sequences, the use of a prime-boost strategy, the administration of a combined vaccine, and the use of liposomes as delivery vehicle.
Gene gun mucosal DNA immunization of sheep with a plasmid expressing the env gene of MVV was used to examine the protection against MVV infection in sheep from a naturally infected flock. For immunization, sheep were primed with a pcDNA plasmid (pcDNA-env) encoding the env of MVV. The results demonstrated a significant early protective effect of this immunization strategy against MVV infection. In addition, another strategy of DNA vaccine candidate against MVV infection was developed and was constructed by cloning genes encoding the MVV gag polyprotein and gag proteins p16 and p25 fused to a β-galactosidase in a plasmid backbone. When transfection of different ovine cells showed a higher protein expression with plasmid lacZp16, a secretory signal (Sc) was introduced to promote antigen secretion and increase its presentation to APCs. The addition of the secretory signal (Sc-p16) led to lower amounts of intracellular antigen/reporter fusion in transfected ovine cells, thus confirming secretion. These findings showed that mice primed with Sc-p16 and boosted with MVV exhibited strong antibody responses.
Creative Biolabs is a highly proactive, robust and diversified company with a strong, scientifically-proven background of viral vaccine development. We have experts who are able to help you with the vaccine development against maedi-visna virus. Our scientists are confident in offering the best services and products upon request!
All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.
